Who
Andrew John Phillips
Director
Company insider
Files Form 4 as: Director, OnKure Therapeutics; Director, MoonLake Immunotherapeutics; Director, Enliven Therapeutics.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 6 Apr 2022
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,195 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,195 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,682 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 6 Feb 2025filed 10 Feb 2025 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,491 at $0.00 | filing |
| 4 Oct 2024filed 8 Oct 2024 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,688 at $0.00 | filing |
| 13 Feb 2024filed 20 Feb 2024 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,364 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,835 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,297 at $0.00 | filing |
| 23 Feb 2023filed 6 Apr 2023 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,567 at $0.00 | filing |
| 6 Apr 2022filed 5 May 2022 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.